Oxygenta Pharmaceutical Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 798135,
    "name": "Oxygenta Pharma",
    "stock_name": "Oxygenta Pharma",
    "full_name": "Oxygenta Pharmaceutical Ltd",
    "name_url": "stocks-analysis/oxygenta-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "61.11",
    "chg": 0.43,
    "chgp": "0.71%",
    "dir": 1,
    "prev_price": "60.68",
    "mcapval": "236.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524636,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE102E01018",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1.81 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/oxygenta-pharma-798135-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Oxygenta Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharma-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3744024",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/OxygentaPharma_mojoScore_3744024.png",
        "date": "2025-12-03 11:08:14",
        "description": "Oxygenta Pharma has experienced a revision in its market evaluation, reflecting shifts in its financial performance and market positioning. This adjustment highlights ongoing challenges within the Pharmaceuticals & Biotechnology sector, particularly for microcap companies facing operational and valuation pressures."
      },
      {
        "title": "Oxygenta Pharmaceutical Sees Extraordinary Buying Interest Amid Upper Circuit Scenario",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-hits-upper-circuit-amidst-unprecedented-buying-interest-3720527",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OxygentaPharmac_only_buyers_3720527.png",
        "date": "2025-11-21 10:10:38",
        "description": "Oxygenta Pharmaceutical has attracted remarkable buying interest today, with the stock hitting an upper circuit and registering only buy orders in the queue. This unusual market behaviour signals a potential multi-day circuit scenario, reflecting strong demand despite recent price pressures and sector trends."
      },
      {
        "title": "Why is Oxygenta Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-oxygenta-pharma-fallingrising-3719348",
        "imagepath": "",
        "date": "2025-11-21 00:49:21",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Oxygenta Pharma’s share price has been on a downward trajectory over the past week, falling by 3.07%, in stark contrast to the Sensex’s gain of 1.37% during the same period. This divergence highlights the stock’s relative weakness amid a generally positive market environment. Over the last month, the stock has declined by 6.44%, while the Sensex has advanced by 1.50%, further emphasising the stock’s underperformance.</p>\n<p>Year-to-date figures paint a more concerning picture, with Oxygenta Pharma down 32.43%, whereas the Sensex has risen by 9.59%. Even over the last year, the stock has lost 22.75%, while the benchmark index gained 10.38%. These figures suggest that despite some longer-term gains over three and five years, the recen..."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Surges 5% Today, Reaching Intraday High of Rs 63.87",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-surges-5-today-reaching-intraday-high-of-rs-6387-3706847",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OxygentaPharmac_only_buyers_3706847.png",
        "date": "2025-11-17 10:20:39",
        "description": "Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with a significant stock increase today, reversing a two-day decline. Despite recent challenges, the stock has shown impressive long-term growth over five years. Current performance metrics indicate mixed technical signals, reflecting ongoing market sentiment and potential sector developments."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Surges 4.99% Today, Reaching Intraday High of Rs 63.99",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-surges-499-today-reaching-intraday-high-of-rs-6399-3701019",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OxygentaPharmac_only_buyers_3701019.png",
        "date": "2025-11-14 10:00:36",
        "description": "Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with the stock rising significantly today, in contrast to a decline in the Sensex. Despite recent challenges, the stock has shown resilience over the past month, outperforming the index, while current trading indicates mixed trends in the short to medium term."
      },
      {
        "title": "Why is Oxygenta Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-oxygenta-pharma-fallingrising-3687134",
        "imagepath": "",
        "date": "2025-11-10 23:00:10",
        "description": "As of 10-Nov, Oxygenta Pharmaceutical Ltd is experiencing a decline in its stock price, currently at Rs 62.40, which reflects a decrease of Rs 2.07 or 3.21%. The stock has been underperforming, having lost 6.64% over the last two days and is currently trading below its recent moving averages, specifically lower than the 5-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock has underperformed its sector by 4.26% today. In terms of returns, over the past week, the stock has decreased by 3.81%, while it has shown a significant decline of 28.66% year-to-date and 29.76% over the past year, despite a strong performance over the last three and five years.\n\nBroader Market Context: In comparison to the benchmark Sensex, which has only decreased by 0.53% over the past week, Oxygenta's short-term performance is notably weaker. The Sensex has shown a positive return of 1.25% over the past month, ..."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Faces Significant Selling Pressure with 35.03% Decline Over Three Months",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-faces-significant-selling-pressure-with-3503-decline-over-three-months-3684736",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OxygentaPharmac_only_sellers_3684736.png",
        "date": "2025-11-10 09:31:43",
        "description": "Oxygenta Pharmaceutical Ltd is experiencing significant selling pressure, with consecutive losses leading to an 8.29% decline over two days. The stock has underperformed against the Sensex, showing a 35.03% drop over the past three months and trading below key moving averages, indicating ongoing challenges in the market."
      },
      {
        "title": "How has been the historical performance of Oxygenta Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-oxygenta-pharma-3683561",
        "imagepath": "",
        "date": "2025-11-09 22:42:18",
        "description": "Answer:\nThe historical performance of Oxygenta Pharma shows significant fluctuations in its financial metrics over the years, with a notable increase in net sales in March 2025 reaching 109.30 Cr, up from 39.64 Cr in March 2024 and 30.99 Cr in March 2023. However, the company has faced challenges with total expenditure, which rose to 119.30 Cr in March 2025 from 49.34 Cr in March 2024, leading to an operating profit of -10.00 Cr in March 2025, slightly worse than -9.70 Cr in the previous year. The profit before tax also declined to -14.35 Cr in March 2025 from -13.87 Cr in March 2024, while the profit after tax was -10.30 Cr, worsening from -3.48 Cr in March 2024. The company's total liabilities increased to 72.62 Cr in March 2025 from 54.46 Cr in March 2024, with total debt at 62.23 Cr. Shareholder's funds remained negative at -25.02 Cr in March 2025, indicating ongoing financial distress. Cash flow from o..."
      },
      {
        "title": "Are Oxygenta Pharma latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-oxygenta-pharma-latest-results-good-or-bad-3682456",
        "imagepath": "",
        "date": "2025-11-08 19:20:17",
        "description": "Oxygenta Pharmaceutical's latest financial results for Q2 FY26 reflect significant operational challenges and a deteriorating financial position. The company reported a net loss of ₹6.11 crores, which represents a substantial decline compared to the previous quarter's performance. Revenue for the quarter was ₹15.13 crores, indicating a drastic quarter-on-quarter decline of 69.42%, despite a modest year-on-year growth of 19.89%. This volatility in revenue generation raises concerns about the sustainability of its business model.\n\nThe operating margin, which fell to -45.14%, marks the worst performance in at least seven quarters, highlighting severe structural issues within the company's cost management and operational execution. Additionally, the profit after tax (PAT) margin deteriorated to -40.38%, reflecting the ongoing struggles to achieve profitability amid rising operational losses.\n\nOn a broader scale..."
      }
    ],
    "total": 206,
    "sid": "798135",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/oxygenta-pharmaceutical-798135"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter Ended December 31 2025. 2. Limited Review Report For The Quarter Ended December 31 2025. 3. Any Other Business With The Permission Of The Chair.",
      "datetime": "30-Jan-2026",
      "details": "Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 inter alia to consider and approve 1. Un-audited Financial results for the quarter ended December 31 2025. 2. Limited Review Report for the quarter ended December 31 2025. 3. Any other business with the permission of the Chair.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "12-Jan-2026",
      "details": "Compliance as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "29-Dec-2025",
      "details": "Closure of Trading Window under SEBI (Prohibition of Insier Trading) Regulations 2015 for the period ending on December 31 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Oxygenta Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions

2025-12-03 11:08:14

Oxygenta Pharma has experienced a revision in its market evaluation, reflecting shifts in its financial performance and market positioning. This adjustment highlights ongoing challenges within the Pharmaceuticals & Biotechnology sector, particularly for microcap companies facing operational and valuation pressures.

Oxygenta Pharmaceutical Sees Extraordinary Buying Interest Amid Upper Circuit Scenario

2025-11-21 10:10:38

Oxygenta Pharmaceutical has attracted remarkable buying interest today, with the stock hitting an upper circuit and registering only buy orders in the queue. This unusual market behaviour signals a potential multi-day circuit scenario, reflecting strong demand despite recent price pressures and sector trends.

Why is Oxygenta Pharma falling/rising?

2025-11-21 00:49:21

Recent Price Movement and Market Comparison Oxygenta Pharma’s share price has been on a downward trajectory over the past week, falling by 3.07%, in stark contrast to the Sensex’s gain of 1.37% during the same period. This divergence highlights the stock’s relative weakness amid a generally positive market environment. Over the last month, the stock has declined by 6.44%, while the Sensex has advanced by 1.50%, further emphasising the stock’s underperformance. Year-to-date figures paint a more concerning picture, with Oxygenta Pharma down 32.43%, whereas the Sensex has risen by 9.59%. Even over the last year, the stock has lost 22.75%, while the benchmark index gained 10.38%. These figures suggest that despite some longer-term gains over three and five years, the recen...

Oxygenta Pharmaceutical Ltd Surges 5% Today, Reaching Intraday High of Rs 63.87

2025-11-17 10:20:39

Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with a significant stock increase today, reversing a two-day decline. Despite recent challenges, the stock has shown impressive long-term growth over five years. Current performance metrics indicate mixed technical signals, reflecting ongoing market sentiment and potential sector developments.

Oxygenta Pharmaceutical Ltd Surges 4.99% Today, Reaching Intraday High of Rs 63.99

2025-11-14 10:00:36

Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with the stock rising significantly today, in contrast to a decline in the Sensex. Despite recent challenges, the stock has shown resilience over the past month, outperforming the index, while current trading indicates mixed trends in the short to medium term.

Why is Oxygenta Pharma falling/rising?

2025-11-10 23:00:10

As of 10-Nov, Oxygenta Pharmaceutical Ltd is experiencing a decline in its stock price, currently at Rs 62.40, which reflects a decrease of Rs 2.07 or 3.21%. The stock has been underperforming, having lost 6.64% over the last two days and is currently trading below its recent moving averages, specifically lower than the 5-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock has underperformed its sector by 4.26% today. In terms of returns, over the past week, the stock has decreased by 3.81%, while it has shown a significant decline of 28.66% year-to-date and 29.76% over the past year, despite a strong performance over the last three and five years. Broader Market Context: In comparison to the benchmark Sensex, which has only decreased by 0.53% over the past week, Oxygenta's short-term performance is notably weaker. The Sensex has shown a positive return of 1.25% over the past month, ...

Oxygenta Pharmaceutical Ltd Faces Significant Selling Pressure with 35.03% Decline Over Three Months

2025-11-10 09:31:43

Oxygenta Pharmaceutical Ltd is experiencing significant selling pressure, with consecutive losses leading to an 8.29% decline over two days. The stock has underperformed against the Sensex, showing a 35.03% drop over the past three months and trading below key moving averages, indicating ongoing challenges in the market.

How has been the historical performance of Oxygenta Pharma?

2025-11-09 22:42:18

Answer: The historical performance of Oxygenta Pharma shows significant fluctuations in its financial metrics over the years, with a notable increase in net sales in March 2025 reaching 109.30 Cr, up from 39.64 Cr in March 2024 and 30.99 Cr in March 2023. However, the company has faced challenges with total expenditure, which rose to 119.30 Cr in March 2025 from 49.34 Cr in March 2024, leading to an operating profit of -10.00 Cr in March 2025, slightly worse than -9.70 Cr in the previous year. The profit before tax also declined to -14.35 Cr in March 2025 from -13.87 Cr in March 2024, while the profit after tax was -10.30 Cr, worsening from -3.48 Cr in March 2024. The company's total liabilities increased to 72.62 Cr in March 2025 from 54.46 Cr in March 2024, with total debt at 62.23 Cr. Shareholder's funds remained negative at -25.02 Cr in March 2025, indicating ongoing financial distress. Cash flow from o...

Are Oxygenta Pharma latest results good or bad?

2025-11-08 19:20:17

Oxygenta Pharmaceutical's latest financial results for Q2 FY26 reflect significant operational challenges and a deteriorating financial position. The company reported a net loss of ₹6.11 crores, which represents a substantial decline compared to the previous quarter's performance. Revenue for the quarter was ₹15.13 crores, indicating a drastic quarter-on-quarter decline of 69.42%, despite a modest year-on-year growth of 19.89%. This volatility in revenue generation raises concerns about the sustainability of its business model. The operating margin, which fell to -45.14%, marks the worst performance in at least seven quarters, highlighting severe structural issues within the company's cost management and operational execution. Additionally, the profit after tax (PAT) margin deteriorated to -40.38%, reflecting the ongoing struggles to achieve profitability amid rising operational losses. On a broader scale...

View All News